This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

Prices will rise in...

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Xavier Gerard, Ph.D.
Field Application Scientist, EMEA at Thermo Fisher Scientific
Speaker

Profile

Xavier Gerard, a scientist specializing in RNA biology, embarked on his academic journey in 2008, completing a MSc in Health and Drug Engineering, Biotechnology, and Management at the Faculty of Pharmacy, University of Grenoble in France. Subsequently, he relocated to Paris to pursue a PhD in Molecular and Cellular Biology at the University of Evry.

Since 2012, Xavier has held various positions as a postdoctoral researcher and R&D scientist in organizations dedicated to health research. His dedication to innovation in RNA biology has been a constant throughout his career, with a focus on advancing the next generation of nucleic acid therapeutics. Notably, he has honed expertise in developing oligonucleotide therapeutics, particularly for addressing genetic retinal diseases, with some projects laying the groundwork for clinical trials.

Currently based in Switzerland, Xavier serves as a Field Application Scientist for the EMEA region at Thermo Fisher Scientific within the Nucleic Acid Therapeutics (NATx) division. In this role, he remains devoted to supporting innovative endeavors and assisting customers in pushing the boundaries of nucleic acid-based therapies.

Agenda Sessions

  • Enhancing the Activity and Delivery of Oligonucleotide Therapeutics with Modified Phosphoramidites and Nucleotides

    07:30